文献速递病毒性肝炎

血清M2BPGi在病毒学缓解时预测慢性乙型肝炎相关肝硬化患者的肝细胞癌和死亡

Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis.
PubMed 文献 · J Infect Dis · 2020-01-01

该回顾性队列研究探讨了抗病毒治疗达到病毒学缓解(HBV DNA <20 IU/mL)时血清Mac-2结合蛋白糖基化异构体(M2BPGi)水平对慢性乙型肝炎相关Child-Pugh A肝硬化患者肝细胞癌(HCC)和死亡的预测价值。衍生队列126例和验证队列145例,平均年龄56岁,衍生队列平均M2BPGi为1.86 cut-off指数(COI)。调整混杂因素后,病毒学缓解时较高的M2BPGi水平显著预测HCC(HR 1.58, 95%CI 1.19-2.10, P=0.002)和死亡(HR 2.17, 95%CI 1.02-4.62, P=0.044),且M2BPGi ≥3 COI在衍生和验证队列中均显著增加HCC和死亡风险。

要点

  • 病毒学缓解时M2BPGi较高者HCC风险增加(HR 1.58),死亡风险增加(HR 2.17)。
  • M2BPGi ≥3 COI在衍生和验证队列中均显著增加HCC和死亡风险。
  • 非HCC患者M2BPGi水平随时间显著下降,且始终低于后续发生HCC者。

核心结论

  • 抗病毒治疗诱导的病毒学缓解时血清M2BPGi水平可预测慢性乙型肝炎相关Child-Pugh A肝硬化患者的HCC发生和死亡。

研究设计与样本

  • 回顾性队列研究,纳入接受长期抗病毒治疗的慢性乙型肝炎相关Child-Pugh A肝硬化患者,衍生队列126例,验证队列145例。

主要发现

  • 衍生队列平均年龄56岁,平均M2BPGi水平为1.86 cut-off指数(COI)。
  • 调整混杂因素后,病毒学缓解时较高M2BPGi水平显著预测HCC(HR 1.58, 95%CI 1.19-2.10, P=0.002)和死亡(HR 2.17, 95%CI 1.02-4.62, P=0.044)。
  • M2BPGi ≥3 COI在衍生和验证队列中均显著增加HCC和死亡风险。
  • 仅在非HCC患者中,连续M2BPGi水平显著下降(P=0.0001),且显著低于后续发生HCC者(P=0.039)。

临床怎么用

  • 对于抗病毒治疗达到病毒学缓解的慢性乙型肝炎相关Child-Pugh A肝硬化患者,可检测血清M2BPGi以协助风险分层。
  • M2BPGi ≥3 COI提示HCC和死亡风险显著增加,应考虑加强监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To investigate serum Mac-2-binding protein glycosylation isomer (M2BPGi) levels in predicting hepatocellular carcinoma (HCC) and mortality at virological remission (VR, HBV DNA <20 IU/mL) following antiviral therapy in chronic hepatitis B (CHB) patients with cirrhosis. METHODS: This retrospective cohort study included patients with CHB-related Child-Pugh A cirrhosis undergoing long-term antiviral therapy. Serum M2BPGi levels were quantified and multivariable Cox proportional hazards regression models were used to identify risk predictors for HCC and death. RESULTS: A total of 126 and 145 patients were included in the derivation and validation cohorts, respectively. The mean age was 56, and the mean M2BPGi level was 1.86 cut-off index (COI) in the derivation cohort. After adjustment for confounders, a higher M2BPGi level at VR significantly predicted HCC (hazard ratio [HR]: 1.58, 95% confidence interval [CI]: 1.19-2.10, P=0.002) and death (HR: 2.17, 95% CI: 1.02-4.62, P=0.044). The M2BPGi ≥3 COI significantly increased the risk of HCC and death in the derivation and validation cohorts. Serial M2BPGi levels declined significantly (P=0.0001) in non-HCC patients only, and remained significantly lower than those who developed HCC afterwards (P=0.039). CONCLUSIONS: Serum M2BPGi levels at antiviral therapy-induced VR predict HCC development and death in patients with CHB-related Child-Pugh A cirrhosis.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Su TH, Peng CY, Tseng TC, et al. Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis. J Infect Dis. 2020. PMID: 31574141. doi:10.1093/infdis/jiz496

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。